Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on May 13, 2020, covering events occurring on May 8, 2020, May 12, 2020, and May 13, 2020. The filing details the entry into material definitive agreements to secure funding for the clinical development of onvansertib, a Phase 1b/2 trial candidate for metastatic colorectal cancer.
Key Financial Metrics and Capital Structure
The filing reports two distinct capital raising transactions:
- POC Capital Transaction (May 8, 2020): The Company received an aggregate issue price of $2,300,000. In exchange, it issued 602,833 shares of Common Stock, 154,670 shares of Series D Preferred Stock, and a warrant exercisable for 859,813 shares of Common Stock.
- Director Transaction (May 12, 2020): The Company sold 447,761 shares of Common Stock to a director at $1.34 per share, generating gross proceeds of approximately $600,000.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels, as this is a current report focused on specific corporate events rather than a periodic financial statement.
Material Changes and Securities Issuance
The primary material change is the issuance of unregistered equity securities under Section 4(a)(2) and Rule 506 exemptions. Key terms include:
- Warrant Terms: The warrant issued to POC Capital is exercisable from November 8, 2020, to November 7, 2025, at an exercise price of $1.50 per share.
- Series D Preferred Stock: 154,670 shares were designated. Each share is convertible into 10 shares of Common Stock. Conversion is subject to a 4.99% beneficial ownership limitation.
- Voting Rights: Series D holders may vote on an as-converted basis, subject to the beneficial ownership limitation.
Outlook, Management Commentary, and Risks
Management announced an agreement with POC Capital to fund the clinical development of onvansertib, described as a first-in-class, third-generation oral and highly selective PLK1 inhibitor. The funding supports a Phase 1b/2 clinical trial in patients with metastatic colorectal cancer (mCRC). The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosures regarding the unregistered sale of securities.
Investor Verification Checklist
- Verify the full terms of the Stock and Warrant Subscription Agreement (Exhibit 10.1) and the Securities Purchase Agreement (Exhibit 10.2).
- Confirm the dilution impact of the 602,833 common shares, 154,670 Series D shares (convertible 10:1), and 859,813 warrant shares.
- Review the press release (Exhibit 99.1) for specific milestones tied to the POC Capital funding.
- Check subsequent filings for the Company's cash position and burn rate to assess runway following these capital raises.